Assessment of Hematopoietic Recovery Following Chemotherapy for Non-Hodgkin's Lymphoma

September 27, 2010 updated by: University of Oklahoma

Assessment of Hematopoietic Recovery Following Chemotherapy for Non-Hodgknin's Lymphoma

A study to determine the accuracy of FLT-PET in quantifying tumor cell proliferation at the initial staging of patients with Non-Hodgkin's Lymphoma in comparison wit the "gold standard" FDG-PET.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

The first primary objective reflects a necessary and preliminary requirement: to reproduce published results and validate the use of FLT-PET. In this study, 35 patients will be selected to undergoing imaging with both FLT and FDG PET.

Study Type

Observational

Enrollment (Anticipated)

35

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73104
        • University of Oklahoma Health Sciences Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Subjects diagnosed with lymphoma and are about to start treatment with chemotherapy

Description

Inclusion Criteria:

  • 18 years or older
  • Women must not be pregnant or breast feeding
  • Histologic diagnosis of non-Hodgkin's lymphoma (any stage)
  • Must undergo treatment with chemotherapy and/or radiotherapy

Exclusion Criteria:

  • May not have received previous therapy with radiopharmaceuticals
  • May not have received prior therapy with cytotoxic chemotherapy and/or monoclonal antibodies

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
1
FLT-PET Scan
Procedure: FLT-PET scan
imaging scan
2
FDG-PET Scan
Procedure: FDG-PET scan
imaging scan

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Staging and ReStaging scans
Time Frame: after hematopoetic recovery
after hematopoetic recovery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Oklahoma

Collaborators

Midwest Medical Isotopes

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2008

Study Registration Dates

First Submitted

October 17, 2008

First Submitted That Met QC Criteria

October 17, 2008

First Posted (Estimate)

October 20, 2008

Study Record Updates

Last Update Posted (Estimate)

September 28, 2010

Last Update Submitted That Met QC Criteria

September 27, 2010

Last Verified

September 1, 2010

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • FLT-NHL

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Non-Hodgkin's Lymphoma

Clinical Trials on FLT-PET scan

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe